Covered recipient · General Payments record
BARRY D BERTOLET
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$74,035.39
136 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,972.00 | 24 |
| Consulting Fee | $26,213.00 | 13 |
| Food and Beverage | $3,356.20 | 85 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,250.00 | 2 |
| Travel and Lodging | $1,159.77 | 10 |
| Education | $84.42 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Esperion Therapeutics, Inc. | $16,914.32 | 16 |
| AstraZeneca Pharmaceuticals LP | $15,889.64 | 24 |
| Medtronic, Inc. | $14,812.59 | 17 |
| Shockwave Medical, Inc | $14,686.20 | 9 |
| Amgen Inc. | $5,498.10 | 10 |
| CARDIVA MEDICAL, INC. | $3,500.00 | 3 |
| Medicure Pharma Inc. | $800.00 | 1 |
| W. L. Gore & Associates, Inc. | $570.51 | 6 |
| BOSTON SCIENTIFIC CORPORATION | $233.76 | 5 |
| ABIOMED | $177.41 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $151.40 | 5 |
| Novartis Pharmaceuticals Corporation | $126.22 | 10 |
| Penumbra, Inc. | $115.94 | 1 |
| Nuwellis, Inc. | $93.46 | 1 |
| Merck Sharp & Dohme Corporation | $88.27 | 6 |
| Abbott Laboratories | $77.21 | 2 |
| Siemens Medical Solutions USA, Inc. | $61.05 | 1 |
| Janssen Pharmaceuticals, Inc | $55.73 | 4 |
| Amarin Pharma Inc. | $52.63 | 3 |
| Osprey Medical Inc | $48.92 | 4 |
| Chiesi USA, Inc. | $33.29 | 2 |
| Philips Electronics North America Corporation | $21.84 | 1 |
| E.R. Squibb & Sons, L.L.C. | $15.73 | 1 |
| Change Healthcare Technologies, LLC | $11.17 | 1 |
Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BARRY D BERTOLET
NPI 1295845444 · CMS profile ID 240622
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
TUPELO, MS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BARRY D BERTOLET, NPI 1295845444, CMS profile ID 240622. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). BARRY D BERTOLET, NPI 1295845444, CMS profile ID 240622. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- BARRY D BERTOLET, NPI 1295845444, CMS profile ID 240622, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
136 matching records · $74,035.39 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–136 of 136.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | $1,500.00 | 04/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838247007 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.81 | 04/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834330877 | CMS |
| Esperion Therapeutics, Inc. | $1,500.00 | 04/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838247003 | CMS |
| Esperion Therapeutics, Inc. | $16.11 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838246999 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9.42 | 04/07/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763358826 | CMS |
| Esperion Therapeutics, Inc. | $1,980.00 | 04/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838246995 | CMS |
| Janssen Pharmaceuticals, Inc | $15.38 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788088643 | CMS |
| CARDIVA MEDICAL, INC. | $1,875.00 | 04/01/2021 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839389821 | CMS |
| Merck Sharp & Dohme Corporation | $16.07 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848692791 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.50 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834326353 | CMS |
| Osprey Medical Inc | $7.84 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 760866664 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $81.43 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777759221 | CMS |
| ABIOMED | $25.42 | 03/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848770247 | CMS |
| ABIOMED | $142.79 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848770249 | CMS |
| AstraZeneca Pharmaceuticals LP | $55.35 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834343051 | CMS |
| Shockwave Medical, Inc | $750.00 | 03/16/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853181715 | CMS |
| Shockwave Medical, Inc | $10.04 | 03/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853185243 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 03/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834323137 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 03/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834346077 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 03/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834351253 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,200.00 | 03/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834339623 | CMS |
| Shockwave Medical, Inc | $20.76 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853182975 | CMS |
| ABIOMED | $9.20 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848770245 | CMS |
| Merck Sharp & Dohme Corporation | $16.93 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848318129 | CMS |
| Amarin Pharma Inc. | $15.41 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815300015 | CMS |
| Medicure Pharma Inc. | $800.00 | 02/22/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827906121 | CMS |
| Osprey Medical Inc | $14.53 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 760866670 | CMS |
| W. L. Gore & Associates, Inc. | $78.05 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844665139 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.47 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834333149 | CMS |
| AstraZeneca Pharmaceuticals LP | $60.48 | 02/09/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834340939 | CMS |
| AstraZeneca Pharmaceuticals LP | $99.41 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834344137 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11.93 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763358824 | CMS |
| Amgen Inc. | $467.00 | 01/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825172767 | CMS |
| Amgen Inc. | $2,800.00 | 01/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825172775 | CMS |
| Amgen Inc. | $94.08 | 01/22/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825172771 | CMS |
| Amgen Inc. | $94.21 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825172779 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,227,874.34 | 73 |
| PY2024 | Recipient | $4,144.67 | 1 |
| PY2024 | Principal investigator | $1,889,813.70 | 86 |
| PY2023 | Principal investigator | $799,184.76 | 96 |
| PY2022 | Principal investigator | $522,959.51 | 138 |
| PY2021 | Principal investigator | $604,820.57 | 137 |
| PY2020 | Recipient | $6,500.00 | 1 |
| PY2020 | Principal investigator | $395,382.59 | 79 |
| PY2019 | Principal investigator | $496,886.73 | 73 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
73 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Medtronic, Inc. | $98,205.00 | 12/31/2025 | Non-covered Recipient Entity Cardiology Associates Of North Ms Pa | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1185005682 |
| Principal investigator 1 | Boston Scientific Corporation | $1,630.00 | 12/16/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571509 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,068.00 | 12/12/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237781 |
| Principal investigator 1 | Medtronic, Inc. | $1,000.00 | 12/05/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL HTN-ON MED Expan | No dispute reported | 06/30/2026 | 1192317202 |
| Principal investigator 1 | Shockwave Medical, Inc | $1,300.00 | 11/24/2025 | Covered Recipient Teaching Hospital North Mississippi Medical Center | Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries | No dispute reported | 06/30/2026 | 1175055767 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,477.00 | 11/19/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237738 |
| Principal investigator 1 | Medtronic, Inc. | $1.00 | 11/10/2025 | Non-covered Recipient Entity North Mississippi Medical Center | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1185005737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,607.00 | 11/07/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237755 |
| Principal investigator 1 | Medtronic, Inc. | $5,090.00 | 11/07/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319020 |
| Principal investigator 1 | Boston Scientific Corporation | $1,220.00 | 11/04/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571507 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,500.00 | 10/24/2025 | Non-covered Recipient Entity Cardiology Associates of North Mississippi PA | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215508792 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 10/24/2025 | Non-covered Recipient Entity Cardiology Associates of North Mississippi PA | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215508797 |
| Principal investigator 1 | Boston Scientific Corporation | $4,160.00 | 10/21/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571505 |
| Principal investigator 1 | Medtronic, Inc. | $73,700.00 | 10/17/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319016 |
| Principal investigator 1 | Medtronic, Inc. | $2,100.00 | 10/17/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319018 |
| Principal investigator 1 | Amgen Inc. | $563.10 | 10/08/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246639965 |
| Principal investigator 1 | Medtronic, Inc. | $555.00 | 09/26/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL HTN-ON MED Expan | No dispute reported | 06/30/2026 | 1192317200 |
| Principal investigator 1 | Medtronic, Inc. | $66,339.00 | 09/26/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1192326223 |
| Principal investigator 1 | Amgen Inc. | $1,555.14 | 09/24/2025 | Non-covered Recipient Entity ARDIOLOGY ASSOCIATES OF NORTH MS PA | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246639175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,501.00 | 09/19/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237723 |
| Principal investigator 1 | Medtronic, Inc. | $1,820.00 | 09/12/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319012 |
| Principal investigator 1 | Medtronic, Inc. | $1,500.00 | 09/12/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319014 |
| Principal investigator 1 | Boston Scientific Corporation | $2,610.00 | 09/09/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571503 |
| Principal investigator 1 | Medtronic, Inc. | $1,738.93 | 09/05/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319010 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,591.16 | 09/02/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190309888 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $87,578.76 | 09/02/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190309892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,742.00 | 08/25/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237732 |
| Principal investigator 1 | Boston Scientific Corporation | $275.00 | 08/05/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | LUX-DX TRENDS | No dispute reported | 06/30/2026 | 1207571459 |
| Principal investigator 1 | Boston Scientific Corporation | $2,865.00 | 08/05/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,241.00 | 07/23/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237681 |
| Principal investigator 1 | Medtronic, Inc. | $32,483.00 | 07/11/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319008 |
| Principal investigator 1 | Medtronic, Inc. | $3.00 | 07/09/2025 | Non-covered Recipient Entity North Mississippi Medical Center | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1185005729 |
| Principal investigator 1 | Boston Scientific Corporation | $950.00 | 07/08/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | LUX-DX TRENDS | No dispute reported | 06/30/2026 | 1207571457 |
| Principal investigator 1 | Boston Scientific Corporation | $2,860.00 | 07/08/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571499 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 07/07/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175237700 |
| Principal investigator 1 | Medtronic, Inc. | $33,732.00 | 07/03/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1192326221 |
| Principal investigator 1 | Shockwave Medical, Inc | $955.89 | 07/02/2025 | Covered Recipient Teaching Hospital North Mississippi Medical Center | Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries | No dispute reported | 06/30/2026 | 1175055753 |
| Principal investigator 1 | Medtronic, Inc. | $3,500.00 | 06/27/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319004 |
| Principal investigator 1 | Medtronic, Inc. | $5,460.00 | 06/27/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319006 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,193.00 | 06/23/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,048.00 | 06/20/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237716 |
| Principal investigator 1 | Medtronic, Inc. | $555.00 | 06/20/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL HTN-ON MED Expan | No dispute reported | 06/30/2026 | 1192317198 |
| Principal investigator 1 | Boston Scientific Corporation | $3,785.00 | 06/17/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571497 |
| Principal investigator 1 | Medtronic, Inc. | $93.00 | 06/12/2025 | Non-covered Recipient Entity North Mississippi Medical Center | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1185005725 |
| Principal investigator 1 | Shockwave Medical, Inc | $955.89 | 05/30/2025 | Covered Recipient Teaching Hospital North Mississippi Medical Center | Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries | No dispute reported | 06/30/2026 | 1175055774 |
| Principal investigator 1 | Shockwave Medical, Inc | $2,500.00 | 05/22/2025 | Non-covered Recipient Entity Cardiology Associates Research | Forward-Shifted Intravascular Lithotripsy (IVL) Technology in a Prospective, Multi-center, Single-arm Investigational Device Exemption (IDE) Study | No dispute reported | 06/30/2026 | 1175052745 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,021.00 | 05/21/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237690 |
| Principal investigator 1 | Boston Scientific Corporation | $635.00 | 05/13/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,499.00 | 04/23/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237771 |
| Principal investigator 1 | Boston Scientific Corporation | $150.00 | 04/22/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571481 |
| Principal investigator 1 | Boston Scientific Corporation | $1,135.00 | 04/22/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571483 |
| Principal investigator 1 | Boston Scientific Corporation | $25,875.00 | 04/22/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571493 |
| Principal investigator 1 | Medtronic, Inc. | $378.00 | 03/28/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192319002 |
| Principal investigator 1 | Shockwave Medical, Inc | $955.89 | 03/27/2025 | Covered Recipient Teaching Hospital North Mississippi Medical Center | Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries | No dispute reported | 06/30/2026 | 1175055744 |
| Principal investigator 1 | Boston Scientific Corporation | $275.00 | 03/25/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | LUX-DX TRENDS | No dispute reported | 06/30/2026 | 1207571455 |
| Principal investigator 1 | Boston Scientific Corporation | $3,120.00 | 03/25/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571491 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,430.07 | 03/24/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190309890 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,493.00 | 03/21/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237748 |
| Principal investigator 1 | Medtronic, Inc. | $55,559.00 | 03/21/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1192326219 |
| Principal investigator 1 | Medtronic, Inc. | $1,000.00 | 03/14/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1192326217 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,703.00 | 02/27/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI, PA | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190302321 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,625.00 | 02/19/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237707 |
| Principal investigator 1 | Boston Scientific Corporation | $2,185.00 | 02/11/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571489 |
| Principal investigator 1 | Medtronic, Inc. | $5.00 | 02/11/2025 | Non-covered Recipient Entity North Mississippi Medical Center | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1185005722 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $25,564.00 | 01/30/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI, PA | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190302319 |
| Principal investigator 1 | Boston Scientific Corporation | $550.00 | 01/28/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | LUX-DX TRENDS | No dispute reported | 06/30/2026 | 1207571453 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $89,883.51 | 01/27/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190309894 |
| Principal investigator 1 | Medtronic, Inc. | $131,448.00 | 01/24/2025 | Non-covered Recipient Entity Cardiology Association Research Llc | SPYRAL AFFIRM | No dispute reported | 06/30/2026 | 1192326215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,797.00 | 01/22/2025 | Non-covered Recipient Entity Crdlgy Associates Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175237674 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $111,086.00 | 01/17/2025 | Non-covered Recipient Entity Urology Prof Assoc | A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (DISCOVER-HCM) | No dispute reported | 06/30/2026 | 1235992283 |
| Principal investigator 1 | Boston Scientific Corporation | $3,535.00 | 01/14/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571485 |
| Principal investigator 1 | Boston Scientific Corporation | $2,300.00 | 01/14/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES RESEARCH LLC | ELEGANCE | No dispute reported | 06/30/2026 | 1207571487 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $60.00 | 01/01/2025 | Non-covered Recipient Entity CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension | No dispute reported | 06/30/2026 | 1190309898 |